Prof. Al-Shamsi is the Director of Oncology Services at Burjeel Holdings in the UAE and GCC. He is also the President of the Emirates Oncology Society and Lead of the Gulf Cancer Society. Additionally, he is an Adjunct Professor of Oncology at the College of Medicine at the University of Sharjah, and the first Emirati to be promoted to full professor in oncology in the UAE. He serves as the Chairman for Colorectal Cancer in the MENA region, appointed by the prestigious National Comprehensive Cancer Network® (NCCN®), and also chairs the Oncology and Hematology Fellowship Training Program for the National Institute for Health Specialties in the UAE.

Prof. Al-Shamsi graduated with honors from the University College Cork in Ireland and completed his residency training in Internal Medicine and fellowship in Medical Oncology at McMaster University in Ontario, Canada. He also completed a postdoctoral clinical fellowship in Gastrointestinal Oncology and Palliative Oncology. He was the first graduate of the prestigious Sheikh Khalifa scholarship for distinguished doctors. He is board-certified from the UK, USA, and Canada in both Internal Medicine and Oncology. Between 2014 and 2017, he served as an Assistant Professor at the University of Texas MD Anderson Cancer Center in Houston, TX, USA.

Prof. Al-Shamsi has established the largest oncology care network in the UAE and built the most comprehensive bone marrow transplant unit at Burjeel Medical City. He established the most comprehensive BMT program in the UAE, which delivered the first adult and pediatric allogeneic BMT for the UAE. He achieved the first European Society for Medical Oncology (ESMO) accreditation for Burjeel Medical City, making it the first and only ESMO-designated oncology center in the UAE.

Prof. Al-Shamsi has published more than 100 peer-reviewed articles in prestigious medical journals such as JAMA Oncology, Lancet Oncology, The Oncologist, BMC Cancer, and others. He published the first book about cancer research in the UAE and the first book about cancer in the Arab world titled “Cancer in the Arab World.” Both books were launched at Expo 2020 and have been downloaded more than 300,000 times in their first year of publication. His research focus is on personalized medicine. In 2016, he and his team identified the non-V600 BRAF subgroup of colorectal cancer and described the FGFR mutation in cholangiocarcinoma. He published the largest studies on somatic mutations in Arab populations for colorectal cancer and breast cancer. His publication about COVID-19 and cancer was named Publication of the Year by the Oncologist Journal in 2020.

In recognition of his exceptional leadership and research, Prof. Al-Shamsi was awarded the prestigious Feigenbaum Leadership Excellence Awards from Sheikh Hamdan Smart University and the Sharjah Award for Volunteering in 2022.

We are looking for collaboration with a multinational team of elite WIN Institutions in order to carry out meaningful clinical research for the benefit of our, and patients worldwide through cutting edge translational genomic studies.  We believe that by combing highest quality international research and clinical experiences from our unique group of patients, with others from around the world is a way to discover unique insights into the genetic causes and more effective treatment of human diseases.